Biopharma reverse mergers rise 1,600% in Q3 to rival IPOs

▤ Summary

Biopharma companies are increasingly using reverse mergers to reach public markets instead of relying only on traditional IPOs. This year, the sector has seen nearly as many reverse mergers as IPOs, and most of the reverse-merger activity has clustered in the current quarter. Investors like the process because it offers more disclosure and visibility than a standard IPO, though the transactions usually take several months to close. The article highlights Obsidian Therapeutics’ reverse merger with Galera Therapeutics as a recent example and shows that biotechs now have more exit and financing options in a stronger market environment.

▦ Linked Companies